X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Fact Sheet, Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Fact Sheet   (ALKE)

Here is the latest financial fact sheet of . For more details, see the quarterly results and share price and chart. For a sector overview, read our pharmaceuticals sector report.

ALKEM LABORATORIES Price History

Price Rs 1,965.5
Mkt Cap Rs m 235,005
Vol '000 0.3
P/E X  
P/CF X 29.9
EPS (TTM) Rs 0.0
% ch % -0.4
No. of shares m 119.57
% ch week % 2.1
% ch 1-mth % -5.2
% ch 12-mth % 6.8
52 week H/L Rs 2,468.0/1,742.0
(As on Oct 17, 2018 12:07:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ALKEM LABORATORIES Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
ALKEM LABORATORIES EQUITY SHARE DATA
High RsNA1,589 
Low RsNA1,232 
Sales per share (Unadj.) Rs313.1417.5 
Earnings per share (Unadj.) Rs32.756.3 
Diluted earnings per shareRs32.856.3 
Cash flow per share (Unadj.) Rs38.764.7 
Dividends per share (Unadj.) Rs012.70 
Adj. dividends per shareRs0.0012.70 
Dividend yield (eoy) %NM0.9 
Book value per share (Unadj.) Rs250.8292.9 
Adj. book value per shareRs250.8292.9 
Shares outstanding (eoy) m119.57119.57 
Bonus/Rights/Conversions  -- 
Price / Sales ratio x03.4 
Avg P/E ratio x025.1 
P/CF ratio (eoy) x021.8 
Price / Book Value ratio x04.8 
Dividend payout %022.6 
Avg Mkt Cap Rs m0168,653 
No. of employees `000NANA 
Total wages/salary Rs m6,4599,171 
Avg. sales/employee Rs ThNMNM 
Avg. wages/employee Rs ThNMNM 
Avg. net profit/employee Rs ThNMNM 
ALKEM LABORATORIES INCOME DATA
Net Sales Rs m37,43449,915 
Other income Rs m1,8101,645 
Total revenues Rs m39,24451,561 
Gross profit Rs m4,2188,482 
Depreciation Rs m7091,006 
Interest Rs m811671 
Profit before tax Rs m4,5088,451 
Minority Interest Rs m0-114 
Prior Period Items Rs m00 
Extraordinary Inc (Exp) Rs m00 
Tax Rs m5921,606 
Profit after tax Rs m3,9166,731 
Gross profit margin %11.317.0 
Effective tax rate %13.119.0 
Net profit margin %10.513.5 
ALKEM LABORATORIES BALANCE SHEET DATA
Current assets Rs m23,38127,062 
Current liabilities Rs m20,06015,324 
Net working cap to sales %8.923.5 
Current ratio x1.21.8 
Inventory Days Days7667 
Debtors Days Days5141 
Net fixed assets Rs m11,42912,610 
Share capital Rs m239239 
"Free" reserves Rs m29,58834,490 
Net worth Rs m29,99135,027 
Long term debt Rs m3341,212 
Total assets Rs m52,95854,387 
Interest coverage x6.613.6 
Debt to equity ratio x00 
Sales to assets ratio x0.70.9 
Return on assets %8.913.6 
Return on equity %13.119.2 
Return on capital %17.524.9 
Exports to sales %9.212.9 
Imports to sales %3.93.1 
Exports (fob) Rs m3,4446,461 
Imports (cif) Rs m1,4561,540 
Fx inflow Rs m3,5166,563 
Fx outflow Rs m2,5903,012 
Net fx Rs m9263,552 
ALKEM LABORATORIES CASH FLOW
From Operations Rs m 3,255 7,259 
From Investments Rs m -2,370 1,864 
From Financial Activity Rs m -518 -9,273 
Net Cashflow Rs m 367 -150 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 66.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 33.1%
FIIs 0.0%
ADR/GDR 0.0%
Free float 0.0%
Shareholders 68,381
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai-13
E-MAIL investors@alkem.com WEB www.alkemlabs.com
TELEPHONE 02239829999 FAX
SECTOR PHARMACEUTICALS GROUP
TR AGENT Link Intime India Pvt Ltd
CHM: Mr. Samprada Singh COMP SEC: Mr. Manish Narang YEAR OF INC: 1973 BSE CODE: 539523 FV (Rs): 2 DIV YIELD (%): 0.6

More Pharmaceuticals Company Fact Sheets:   LUPIN LTD  INDOCO REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  AMAR REMEDIES  

Compare ALKEM LABORATORIES With:   LUPIN LTD  INDOCO REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  AMAR REMEDIES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 300 Points Up; Infosys Rallies on Strong Q2 Result(09:30 am)

Asian stocks are higher today. Japan's Nikkei rose 1.3%. MSCI's broadest index of Asia-Pacific shares outside Japan added 0.5% and South Korea 1.5%.

Views on news

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS